Ovoca Bio PLC
LSE:OVB

Watchlist Manager
Ovoca Bio PLC Logo
Ovoca Bio PLC
LSE:OVB
Watchlist
Price: 1.7 GBX Market Closed
Market Cap: 1.4m GBX
Have any thoughts about
Ovoca Bio PLC?
Write Note

Ovoca Bio PLC
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ovoca Bio PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Ovoca Bio PLC
LSE:OVB
Net Income (Common)
-€3.6m
CAGR 3-Years
-1%
CAGR 5-Years
-12%
CAGR 10-Years
8%
Perrigo Company PLC
NYSE:PRGO
Net Income (Common)
-$159.7m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Net Income (Common)
$463.2m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
31%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Net Income (Common)
-$72.6m
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
-3%
G
GH Research PLC
NASDAQ:GHRS
Net Income (Common)
-$35.6m
CAGR 3-Years
-329%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Net Income (Common)
€75.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
No Stocks Found

Ovoca Bio PLC
Glance View

Market Cap
1.5m GBX
Industry
Pharmaceuticals

Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.

OVB Intrinsic Value
2.98 GBX
Undervaluation 43%
Intrinsic Value
Price

See Also

What is Ovoca Bio PLC's Net Income (Common)?
Net Income (Common)
-3.6m EUR

Based on the financial report for Jun 30, 2024, Ovoca Bio PLC's Net Income (Common) amounts to -3.6m EUR.

What is Ovoca Bio PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
8%

Over the last year, the Net Income (Common) growth was -53%. The average annual Net Income (Common) growth rates for Ovoca Bio PLC have been -1% over the past three years , -12% over the past five years , and 8% over the past ten years .

Back to Top